Clinical Breast Cancer Registry of IR. Iran (CBCR-IR): Study Protocol and First Results

Monireh Sadat Seyyedsalehi, Azin Nahvijou, Shaghayegh Haghjooy Javanmard, Mojtaba Vand Rajabpour, Amirreza Manteghinejad, Habibollah Pirnejad, Zahra Niazkhani, Arash Golpazir Sorkheh, Maryam Baniamer, Jamshid Anasari, Masoud Bahrami, Maryam Marzban, Atefeh Esfandiari, Seyedeh Masoumeh Ghoreishi, Novin Nikbakhsh, Yahya Baharvand Iran Nia, Shahram Ahmadi Somaghian, Mohammad Taghi Ashoobi, Fataneh Bakhshi, Alireza Ansari-MoghaddamMahdieh Bakhshi, Maryam Moradi Binabaj, Hassan Nourmohammadi, Ramesh Omranipour, Kazem Zendehdel*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

6 Downloads (Pure)

Abstract

BACKGROUND: 

Breast cancer (BC), as a significant global health problem, is the most common cancer in women. Despite the importance of clinical cancer registries in improving the quality of cancer care and cancer research, there are few reports on them from low- and middle-income countries. We established a multicenter clinical breast cancer registry in Iran (CBCR-IR) to collect data on BC cases, the pattern of care, and the quality-of-care indicators in different hospitals across the country.

METHODS: 

We established a clinical cancer registry in 12 provinces of Iran. We defined the organizational structure, developed minimal data sets and data dictionaries, verified data sources and registration processes, and developed the necessary registry software. During this registry, we studied the clinical characteristics and outcomes of patients with cancer who were admitted from 2014 onwards.

RESULTS: 

We registered 13086 BC cases (7874 eligible cases) between 1.1.2014 and 1.1.2022. Core needle biopsy from the tumor (61.25%) and diagnostic mammography (68.78%) were the two most commonly used diagnostic methods. Stage distribution was 2.03% carcinoma in situ, 12% stage I, 44.65% stage II, 21.32% stage III, and 4.61% stage IV; stage information was missing in 1532 patients (19.46%). Surgery (95.01%) and chemotherapy (79.65%) were the most common treatments for all patients.

CONCLUSION: 

The information provided by this registry can be used to evaluate and improve the quality of care for BC patients. It will be scaled up to the national level as an important resource for measuring quality of care and conducting clinical cancer research in Iran.

Original languageEnglish
Pages (from-to)607-617
Number of pages11
JournalArchives of Iranian Medicine
Volume26
Issue number11
DOIs
Publication statusPublished - 1 Nov 2023

Bibliographical note

© 2023 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Fingerprint

Dive into the research topics of 'Clinical Breast Cancer Registry of IR. Iran (CBCR-IR): Study Protocol and First Results'. Together they form a unique fingerprint.

Cite this